Open-Label Placebo Plus Treatment Rationale Effective for PMS
By Elana Gotkine HealthDay Reporter
FRIDAY, March 28, 2025 -- Open-label placebo (OLP) provided with a treatment rationale is effective and safe for premenstrual syndrome (PMS), according to a study published online March 25 in BMJ Evidence-Based Medicine.
Antje Frey Nascimento, from the University of Basel in Switzerland, and colleagues conducted a randomized controlled trial involving 150 women aged 18 to 45 years with PMS or premenstrual dysphoric disorder. Participants were randomly assigned to treatment as usual (TAU; 50 women), OLP without treatment rationale (OLP−; 50 women), or OLP with treatment rationale (OLP+; 50 women); OLP consisted of two placebo pills per day for six weeks.
The researchers found that across three menstrual cycles (MC1 to MC3), there was a difference between the groups in symptom intensity and interference. At MC3, mean symptom intensity was lower for OLP+ versus TAU and OLP− (b = −9.97 and −6.10), while no difference was seen between TAU and OLP−. At MC3, mean interference was lower for OLP+ than for TAU or OLP− (b = −1.23 and −1.10), with no difference between TAU and OLP−. There were reports of four nonserious adverse events in OLP− and OLP+ (one and three, respectively). High adherence was seen to the OLP intervention (93.18 ± 18.95 percent), with no between-group difference.
"Considering our results as much as the individual and societal burden of PMS, OLP treatment could serve as an acceptable, efficacious, and safe intervention for PMS," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Female PCPs Have Equal/Better Quality Outcomes Than Male PCPs
TUESDAY, May 20, 2025 -- Female primary care physicians (PCPs) in value-based payment models have equal or better quality outcomes and higher earning than their male counterparts...
Accurate Risk Prediction Model Developed for Pediatric Pneumonia
TUESDAY, May 20, 2025 -- An accurate risk prediction model has been developed for children younger than 14 years with community-acquired pneumonia (CAP), according to a study...
AAP Updates Guidelines for Pediatric Atopic Dermatitis Management
MONDAY, May 19, 2025 -- In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for the treatment of children...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.